Rainbow Children’s Medicare Q4 FY26: Growth, New Beds, and the Next Fight for Utilization

Rainbow Children’s Medicare ended Q4 FY26 with its highest ever quarterly revenue, supported by improving volumes across the network and continued traction in newer units. Consolidated revenue from operations rose to INR 459.9 crores in Q4 FY26, up 24% year on year. EBITDA increased 26% to INR 144.7 crores, with the margin broadly stable at 31.5% (versus 31.0% in Q4 FY25). Reported PAT grew 38% to INR 78.2 crores, aided by a deferred tax credit in the quarter.

For FY26, revenue from operations reached INR 1,703.1 crores, up 12.4% versus FY25. EBITDA (post Ind AS 116 and excluding other income) was INR 544.2 crores, up 11.1%, with FY26 margin at 32.0%. PAT for the year rose 15.3% to INR 281.5 crores, with PAT margin improving to 16.5%.

The operating context matters. FY26 was described by management as a landmark year, with nearly 500 beds added, the highest annual capacity addition in the company’s history. When a hospital chain scales capacity this quickly, the near-term trade-off is typically utilization dilution. In Rainbow’s case, FY26 occupancy declined to 46.3% from 50.5% in FY25, even as average revenue per occupied bed increased.

Volumes up, occupancy still the key variable

Operational KPIs in Q4 FY26 showed healthy demand momentum. Inpatient discharges increased 18% year on year to 27,165. Outpatient consultations rose 19% to 424,702. Deliveries increased 22% to 5,138. Despite these volume gains, occupancy in Q4 was 45.3%, slightly lower than 46.5% in Q4 FY25.

The company also disclosed a split between mature and new hospitals. Mature hospitals delivered higher occupancy at 51.8% in Q4 and improved ARPOB at INR 67,239. New hospitals operated at lower occupancy of 35.9% in Q4, consistent with ramp-up dynamics, but still showed ARPOB improvement to INR 52,419.

For the full year, the picture is similar. FY26 volumes improved: IP discharges were 104,514 (up 6%), OP consultations were 1,598,970 (up 12%), and deliveries were 19,228 (up 11%). FY26 ARPOB increased to INR 60,141 (up 11%), while ALOS reduced to 2.71 days (down 5%), reflecting the underlying characteristics of women and children healthcare.

Management attributed part of the FY26 slowdown in mature occupancy to weaker seasonal uplift in Q2 and Q3 and reiterated a priority to reduce dependence on seasonality by strengthening the specialty mix and deepening service lines.

Expansion engine: hub-and-spoke, acquisitions, and greenfield pipeline

Rainbow continues to position itself as a focused women and children healthcare platform built on a hub-and-spoke design. The model concentrates tertiary and quaternary capabilities in hubs, while spokes provide emergency, obstetrics, and pediatrics at scale and refer complex cases upward. The company’s footprint in FY26 covered 24 hospitals and 5 out-patient clinics across 9 cities, with total capacity beds of 2,435.

FY26 included two acquisitions: Prashanthi Hospital in Warangal and Pratiksha Hospital in Guwahati. Management stated these acquired units have integrated seamlessly and are scaling well. In addition, Rainbow commissioned new facilities in Rajahmundry, HRBR and Electronic City in Bengaluru, along with the Mahadevapura IVF centre.

The expansion plan disclosed in the presentation points to growth in multiple clusters. The company outlined planned additions in Coimbatore (about 130 beds), Gurugram Sector 44 (about 325 beds) and Sector 56 (about 125 beds), Pune (about 150 beds), and a Bengaluru spoke at Seegehalli (80 beds). Management also discussed an Indore entry: immediate deployment of Rainbow services inside an existing multi-specialty hospital, followed by a dedicated 100-bed women and children hospital on a long-term lease model, with Rainbow investing in fit-outs and equipment.

The message from management is that the next phase is less about opening hospitals and more about improving occupancy, sharpening service mix, and driving operating leverage as the network matures.

Fertility becomes visible in the revenue mix

Fertility and IVF services are emerging as an incremental growth lever. Management disclosed that IVF contributed 3.7% of total FY26 revenue, increasing to about 4.1% in Q4. IVF revenue for FY26 was stated at INR 61.4 crores.

The company’s strategy is to expand fertility through a mix of in-hospital services and standalone centres, supported by internal referrals and direct patient engagement. Management expects the fertility business to grow around 25% year on year for at least the next three years.

International patient revenue was disclosed at about INR 28.9 crores for FY26 and was described as broadly flat, with management citing geopolitical disruptions and travel issues.

Capital allocation and execution focus

On funding, management stated the company has no debt on its books and holds liquidity of about INR 594 crores. The CFO indicated that expansion and capex plans are expected to be funded through internal cash generation. Operating cash flow to pre Ind AS EBITDA was stated at about 72%, supporting the claim of healthy cash conversion.

Capex disclosures included maintenance capex of about INR 45 crores per year. On growth capex, management highlighted that Gurugram projects are the largest component and referenced incremental investment of about INR 400 crores, with a broader comment of INR 400 to 500 crores over the next two years. For other projects, capex intensity was guided at about INR 65 to 70 lakhs per bed.

Alongside capex, the CEO described a shift toward building a more data-driven execution culture, with stronger dashboarding, review cadence and accountability at hospital level. Technology initiatives mentioned included implementation of a new CRM platform and a new Hospital Information System, aimed at improving marketing effectiveness and conversion across the patient journey.

Takeaways

Rainbow’s FY26 can be read as a capacity-building year that is now turning into a utilization and execution year. Q4 performance showed the demand engine is intact, with strong growth in discharges, consultations and deliveries. But the occupancy decline over FY26 underscores why management has placed asset utilization, standardization and service mix at the center of the next phase.

The company is also adding new levers. Fertility is now a measurable contributor, and management expects it to compound faster than the core business. With a stated no-debt balance sheet and internal funding approach, the near-term focus shifts to execution quality: ramping new hospitals, improving mature occupancy back toward the levels management expects, and delivering consistent patient experience across an expanding geography.